SAR153191 (REGN88)
Проводит Sanofi
Страница компанииA Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01146652/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 2023 чел. во всех странах исследования.
- Плановая дата окончания (12.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 5
Критерии включения
- Main study:
- Participants with RA who were previously randomized in the sarilumab RA clinical program: e.g., the EFC11072 study, ACT11575 study, EFC10832 study, SFY13370, and EFC13752 study.
- Sub-study:
- Participants enrolled in the LTS11210 study who were receiving either sarilumab 200mg q2w PFS or sarilumab 150mg q2w PFS and who were able and willing to participate in this sub-study.
- Participants who had been enrolled in the main study for at least 24 weeks. Participants must sign a sub-study written informed consent prior to any sub-study related procedure.
Критерии невключения
- Main study:
- Participants with any adverse event (AE) led to permanent study drug discontinuation from a prior study.
- Participants with an abnormality(ies) or AEs that per investigator judgment would adversely affect participation of the participant in the study.
- Sub-study: There are no additional exclusion criteria to those defined in main study.
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Источник: ClinicalTrials.gov, NCT01146652 · запись обновлена в реестре 28 марта 2022.
Дизайн и результаты
Что измеряют — первичные конечные точки (5), вторичных — 35
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)
- Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System — From Week 24 to 36
- Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System — From Week 24 to 36
- Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System — From Week 24 to 36
- Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System — From Week 24 to 36
Цель исследования
Main Study:
Primary Objective:
Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA).
Secondary Objective:
Assess the long term efficacy of sarilumab in participants with RA.
Sub-Study:
This phase 3, open label sub-study was aimed to assess the usability of PFS-S when used by participants with moderate or severe RA, or their professional or non-professional healthcare providers in an unsupervised real-world situation. To mimic the real-world practice, the sub-study was incorporated into the LTS11210 study without additional visits compared to the scheduled visits in the main study. The duration of this sub-study was 12 weeks.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01146652 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.